Invasive aspergillosis due to azole-resistant Aspergillus fumigatus is difficult to manage. We describe a case of azole-resistant invasive aspergillosis in a female bottlenose dolphin, who failed to respond to voriconazole and posaconazole therapy. As intravenous therapy was precluded, high dose posaconazole was initiated aimed at achieving trough levels exceeding 3 mg/l. Posaconazole serum levels of 3-9.5 mg/l were achieved without significant side-effects. Follow-up bronchoscopy and computed tomography showed complete resolution of the lesions.
Introduction
Azoles remain the corner-stone of prevention and treatment of aspergillus diseases, including acute invasive aspergillosis (IA) [1] . However, the clinical use of azoles is threatened by the emergence of azole resistance in Aspergillus fumigatus, the primary cause of IA in many regions of the world [2] . Resistance that arises through the environmental use of azole fungicides is believed to be an important driver of azole-resistant cases [3] . This route of resistance development proves a clinical challenge with cases of azole-resistant IA occurring in patients without previous azole therapy [4, 5] , and cases of azole-susceptible and azole-resistant A. fumigatus co-infection [6] . Resistance mutations commonly confer resistance to multiple azole drugs, including the recently clinically-licensed isavuconazole [7] . However, based on in vitro and experimental models it was hypothesized that low-level azoleresistant A. fumigatus infection might be successfully treated with voriconazole or posaconazole provided that the treatment dose and exposure could be increased [8] .
We describe a case of azole-resistant IA in a bottlenose dolphin that was successfully managed by increasing posaconazole exposure.
Case
A 10 year old female captive bottlenose dolphin (Tursiops truncatus), weighing 175 kg, was treated with antibiotics for bacterial pneumonia caused by Vibrio alginolyticus. Treatment follow-up was conducted with blood samples, CT-scans, bronchoscopies, and protected brush samples from the tracheal and/or bronchial mucosa for histopathology and bacterial and fungal culture ( Fig. 1 ).
The bacterial pneumonia required long-term antibiotic treatment and 6 months into therapy she developed multiple white, raised lesions in the trachea and bronchi, one of which was sampled with protected brush during bronchoscopy. No fungi were cultured but based on the bronchoscopic appearance of the lesions a Candida infection was suspected. Treatment with oral voriconazole with a loading dose of 5.5 mg/kg per day during 3 days and a maintenance dose of 5.5 mg/kg per week (given in one single dose) was started. Follow-up bronchoscopies were performed one, two and three months after voriconazole treatment was started, showing no improvement. Fungal culture of a protected brush sample, taken at one and two months of voriconazole therapy remained negative, but at three months A. fumigatus was cultured. Retrospective analysis of a serum sample indicated the presence of circulating galactomannan (GM; GM-index 6.5 was found to be resistant to voriconazole with a MIC of > 16 mg/l and a posaconazole MIC of 0.5 mg/l. The strain harbored the TR 46 /Y121F/ T289A resistance mutation in the cyp51A-gene. Treatment was then changed to posaconazole at a dose of 600 mg/day (day 0). The oral solution formulation of posaconazole was used, which was incorporated in gelatin capsules and placed into the fish she was fed. The daily dose was divided into two doses and administered in the morning and late afternoon. Posaconazole therapeutic drug monitoring was performed aiming at a target trough level of > 1 mg/l. The clinical condition of the dolphin initially improved and follow-up bronchoscopy on days 29, 101, and 232 showed stable disease. Monitoring of posaconazole plasma levels confirmed levels of > 1 mg/l. However, the clinical condition of the dolphin deteriorated and a new bronchoscopy on day 279 showed increased lesion size. The posaconazole dose was increased on day 286 to achieve plasma levels above 2 mg/l. However, this did not result in clinical improvement nor reduction of the size of the trachea lesions.
After 344 days of posaconazole therapy, a higher exposure target was advised based on preclinical studies, aiming at a plasma level of > 3 mg/l [8] . This drug level was first achieved on day 356 of posaconazole therapy. After initial clinical deterioration and stable size of the lesions, the dolphin started to improve clinically, which was supported by resolution of the lesions on the CT-scan (Fig. 2 ). The improvement further was confirmed with bronchoscopy showing complete resolution of the lesions on day 459. Posaconazole plasma levels varied between 3 and 9.5 mg/l, with doses ranging from 800 to 1800 mg/day ( Fig. 3) . After a total treatment duration of 593 days posaconazole therapy was discontinued.
The A. fumigatus isolate recovered from the dolphin was identified using beta-tubulin sequencing. MIC-testing using the EUCAST microdilution reference method showed a MIC of 1 mg/l for amphotericin B, high level-resistance (MIC > 16 mg/l) for itraconazole and voriconazole, and low-level resistance for posaconazole, 0.5 mg/l. A TR 46 / Y121F/T289A resistance mutation was identified.
Discussion
We describe a case of pulmonary IA due to A. fumigatus in a bottlenose dolphin that was complicated by azole resistance. The fungus was cultured from plaques in the trachea and bronchi that were visualized through bronchoscopy, and computed tomography showed pulmonary lesions consistent with fungal disease. Furthermore, circulating GM was detected in the serum at diagnosis. Although GM detection is a well validated diagnostic tool in humans for the diagnosis of invasive aspergillosis and for treatment response evaluation [9, 10] , the performance of the assay in dolphins remains unclear. As IA is the most commonly reported in fungal disease in captive and free-ranging bottlenose dolphins, [11] [12] [13] further studies are needed to determine the performance of this biomarker in dolphins and other cetaceans. In addition to bronchoscopy, the presence of circulating GM would help to diagnose Aspergillus infection and possibly be useful for monitoring of treatment response. GM however does not identify the species of Aspergillus that is causing the fungal pneumonia, nor does it provide information regarding the presence of resistance. Additional tests would be required either through culture or molecular tests of respiratory specimens. PCR-tests that identify the most prevalent Aspergillus species as well as the presence of azole resistance mutations are commercially available [14] . In humans such assays enabled the detection of azole-resistant A. fumigatus directly in BAL-fluid [14, 15] . The A. fumigatus strain recovered from our case harbored a resistance mutation that is associated with environmental resistance selection [5] , indicating that the dolphin inhaled A. fumigatus conidia that were already azole-resistant.
Treatment options in humans and animals with azole-resistant IA are limited. Experts recommended to move away from azole monotherapy when resistance is documented, switching to liposomal amphotericin B or voriconazole and echinocandin combination therapy [16] . In vitro and in vivo studies indicate that the activity of polyenes and echinocandins are not affected by the presence of azole resistance mutations [17] [18] [19] . Furthermore, voriconazole and anidulafungin combination therapy was shown to be effective in an animal model of disseminated IA due to A. fumigatus with low-level voriconazole resistance (MIC of 4 mg/l). However, the efficacy of the combination against voriconazole high-level resistant A. fumigatus has not been studied [18] . There is concern that voriconazole will not be effective in high-level resistant A. fumigatus infection and combination therapy will solely rely on anidulafungin efficacy, which is suboptimal [18] .
As intravenous therapy was no option in treating the dolphin, it was decided to increase the exposure of posaconazole. Using results of pharmacokinetic and pharmacodynamic in vitro and in vivo models we have previously attempted to bridge these experimental results to human infection by calculating which posaconazole exposure would be required in relation to the A. fumigatus MIC to treat successfully [8] . For each MIC the corresponding posaconazole exposure and plasma level were determined [8] . Based on our analysis a posaconazole plasma-level of 3.09-3.33 mg/l would be required to treat an infection with a posaconazole MIC of 0.5 mg/l and 6.18-6.66 mg/l for a MIC of 1.0 mg/l [8] . Indeed when a plasma level of > 3 mg/l was achieved in the dolphin, gradual clinical response was documented without significant toxicity ultimately leading to clinical cure.
In the dolphin very high drug exposures were achieved using the oral solution formulation, but in humans posaconazole drug levels above 3 mg/l could not be achieved due to limited bioavailability associated with the oral suspension. However, phase I and phase II pharmacokinetic studies indicate that a posaconazole plasma level above 3 mg/l can be achieved using the new intravenous and tablet formulations, without significant side-effects [20] . As the majority of azole-resistant A. fumigatus isolates show low-level resistance to posaconazole, i.e. within the 0.5 mg/l to 1 mg/l MIC range [17] , intravenous posaconazole might be a treatment option in human cases of azole-resistant IA.
Our study shows proof-of-principle of high-dose posaconazole for the treatment of IA due to posaconazole low-level-resistant A. fumigatus. With the availability of new posaconazole formulations further studies need to explore this option for the management of azole-resistant IA in animals and humans.
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